CN118574619A - 吉泊达星和万古霉素用于治疗由腐生葡萄球菌引起的感染 - Google Patents

吉泊达星和万古霉素用于治疗由腐生葡萄球菌引起的感染 Download PDF

Info

Publication number
CN118574619A
CN118574619A CN202380017824.7A CN202380017824A CN118574619A CN 118574619 A CN118574619 A CN 118574619A CN 202380017824 A CN202380017824 A CN 202380017824A CN 118574619 A CN118574619 A CN 118574619A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
vancomycin
staphylococcus saprophyticus
gemfibrozil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380017824.7A
Other languages
English (en)
Chinese (zh)
Inventor
N·斯坎加雷拉-欧曼
J·韦斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CN118574619A publication Critical patent/CN118574619A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202380017824.7A 2022-01-21 2023-01-19 吉泊达星和万古霉素用于治疗由腐生葡萄球菌引起的感染 Pending CN118574619A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263301522P 2022-01-21 2022-01-21
US63/301,522 2022-01-21
PCT/EP2023/051177 WO2023139147A1 (en) 2022-01-21 2023-01-19 Gepotidacin and vancomycin for use in the treatment of an infection caused by staphylococcus saprophyticus

Publications (1)

Publication Number Publication Date
CN118574619A true CN118574619A (zh) 2024-08-30

Family

ID=85108785

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380017824.7A Pending CN118574619A (zh) 2022-01-21 2023-01-19 吉泊达星和万古霉素用于治疗由腐生葡萄球菌引起的感染

Country Status (6)

Country Link
US (1) US20250099535A1 (https=)
EP (1) EP4465989A1 (https=)
JP (1) JP2025502442A (https=)
CN (1) CN118574619A (https=)
CA (1) CA3240991A1 (https=)
WO (1) WO2023139147A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008240764C1 (en) 2007-04-20 2011-10-20 Glaxo Group Limited Tricyclic nitrogen containing compounds as antibacterial agents
EP3946342A1 (en) * 2019-04-03 2022-02-09 GlaxoSmithKline Intellectual Property Development Limited Gepotidacin for use in the treatment of bacterial urinary tract infections

Also Published As

Publication number Publication date
WO2023139147A1 (en) 2023-07-27
CA3240991A1 (en) 2023-07-27
EP4465989A1 (en) 2024-11-27
JP2025502442A (ja) 2025-01-24
US20250099535A1 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
US8153166B2 (en) Composition for prophylaxis or treatment of urinary system infection and method thereof
Mikuniya et al. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model
US9034918B2 (en) Composition including at least one trans-cinnamaldehyde and the use thereof in the treatment of bacterial infections, specifically in the treatment of nosocomial infections
Nicolle et al. Prospective, randomized, placebo-controlled trial of norfloxacin for the prophylaxis of recurrent urinary tract infection in women
US20020086867A1 (en) Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
JP2010174032A (ja) 微生物の院内感染症の治療用医薬の製造におけるタウロリジンまたはタウラルタムのような抗微生物薬剤の使用
KR20200026118A (ko) 헬리코박터 파일로리 제균용 조성물
CN114828854A (zh) 用于治疗细菌性尿路感染的吉泊达星
JP2022539583A (ja) マイコプラズマ・ジェニタリウムによって引き起こされる感染症の治療のための組合せ
Raz et al. Intravenous administration of gentamicin once daily versus thrice daily in adults
CN116350628B (zh) Su3327在制备降低多黏菌素细胞毒性和肾毒性的药物中的用途
JP2002500189A5 (https=)
CN118574619A (zh) 吉泊达星和万古霉素用于治疗由腐生葡萄球菌引起的感染
CN101543506A (zh) 预防或治疗猪链球菌病的复方抗生素组合物
López-Brea et al. Study of the combination of ranitidine bismuth citrate and metronidazole against metronidazole-resistant Helicobacter pylori clinical isolates.
BRPI0918593B1 (pt) composição farmacêutica para uso no tratamento de infecções sexualmente transmitidas
US7595328B2 (en) Methods of use of quinolone compounds against pneumococcal and Haemophilus bacteria
KR20250012088A (ko) 항생제 조합 요법
CA2468033C (en) A method of treating bacterial infections using gemifloxacin or a salt thereof and a carbapenem antibacterial agent
PT1458391E (pt) Um processo para tratamento de infecções bacterianas através do uso de gemifloxacina ou um seu sal e um antibiótico b-lactâmico
CN109045044A (zh) 一种复方药剂及其制备方法、用途
US20040023983A1 (en) Methods of use of fluoroquinolone compounds against pathogenic helicobacter bacteria
Weigelt et al. Use of quinolones in surgery and obstetrics and gynecology
CN114366730A (zh) 没食子酸及包含其的药物组合物用于治疗细菌性前列腺炎的应用
KR20030060928A (ko) 병원성 헬리코박터 박테리아에 대한 플루오로퀴놀론화합물의 사용방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination